Allergan PLC (NYSE:AGN) has been given a $294.00 price objective by research analysts at Bank of America Corp. in a research report issued to clients and investors on Tuesday. The firm presently has a a “buy” rating on the stock. Bank of America Corp.’s target price suggests a potential upside of 23.18% from the company’s current price.

A number of other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald cut shares of Allergan PLC from a “buy” rating to a “hold” rating in a research note on Wednesday. Mizuho reaffirmed a “buy” rating and set a $305.00 price target on shares of Allergan PLC in a research note on Wednesday, September 14th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Allergan PLC in a research note on Monday, September 12th. Piper Jaffray Cos. reaffirmed a “neutral” rating and set a $227.00 price target on shares of Allergan PLC in a research note on Tuesday, August 30th. Finally, Vetr raised shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $288.87 price target on the stock in a research note on Monday, August 22nd. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $308.54.

Shares of Allergan PLC (NYSE:AGN) traded down 0.149% during trading on Tuesday, reaching $238.315. 2,840,673 shares of the company’s stock were exchanged. Allergan PLC has a 52 week low of $195.50 and a 52 week high of $322.68. The stock has a market capitalization of $94.36 billion, a price-to-earnings ratio of 22.690 and a beta of 0.73. The stock has a 50 day moving average price of $245.54 and a 200-day moving average price of $243.04.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/allergan-plc-agn-given-a-294-00-price-target-at-bank-of-america-corp.html

Allergan PLC (NYSE:AGN) last posted its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.34 by $0.01. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the company posted $4.41 EPS. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. Analysts predict that Allergan PLC will post $14.01 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of AGN. Capstone Asset Management Co. increased its stake in shares of Allergan PLC by 0.6% in the first quarter. Capstone Asset Management Co. now owns 14,787 shares of the company’s stock valued at $3,963,000 after buying an additional 86 shares during the period. Davis R M Inc. increased its stake in shares of Allergan PLC by 11.5% in the first quarter. Davis R M Inc. now owns 2,154 shares of the company’s stock valued at $577,000 after buying an additional 223 shares during the period. Gillespie Robinson & Grimm Inc. increased its stake in Allergan PLC by 2.1% in the first quarter. Gillespie Robinson & Grimm Inc. now owns 78,043 shares of the company’s stock worth $16,948,000 after buying an additional 1,632 shares during the last quarter. Regent Investment Management LLC increased its stake in Allergan PLC by 1.0% in the first quarter. Regent Investment Management LLC now owns 4,619 shares of the company’s stock worth $1,238,000 after buying an additional 44 shares during the last quarter. Finally, OLD National Bancorp IN increased its stake in Allergan PLC by 0.6% in the first quarter. OLD National Bancorp IN now owns 32,693 shares of the company’s stock worth $8,763,000 after buying an additional 188 shares during the last quarter. 85.19% of the stock is owned by institutional investors.

About Allergan PLC

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.